312 Three-year outcomes with first-line pembrolizumab for metastatic non–small-cell lung cancer (NSCLC) with a very high PD-L1 tumor proportion score (TPS) ≥ 90%
oleh: Mark Awad, Giuseppe Lamberti, Lynette Sholl, Joao Victor Alessi, Stephanie Alden, Victor Vaz, Adriana Barrichello
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2021-11-01 |
Deskripsi
No description available for this item.